Glioblastoma, IDH-wildtype Clinical Trials in Boston, Massachusetts

6 studies are recruiting for glioblastoma, idh-wildtype in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

   This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Tufts Medical Center, Boston, Massachusetts

   Locations

   8 in total

   Run by

   Neonc Technologies, Inc.

   See if you can join NCT06047379 on ClinicalTrials.gov

2. The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)

   Previous evidence has indicated that resection for recurrent glioblastoma might benefit the prognosis of these patients in terms of overall survival. However, the demonstrated safety profile of this approach is contradictory in the literature and the specific benefits in distinct clinical and molec…

   Stage

   Not phased

   Ages

   18 to 90

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   8 in total

   Run by

   Jasper Gerritsen

   See if you can join NCT06283927 on ClinicalTrials.gov

3. The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)

   A greater extent of resection of the contrast-enhancing (CE) tumor part has been associated with improved outcomes in high-grade glioma patients. Recent results suggest that resection of the non-contrast-enhancing (NCE) part might yield even better survival outcomes (supramaximal resection, SMR). T…

   Stage

   Not phased

   Ages

   18 to 90

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   8 in total

   Run by

   Jasper Gerritsen

   See if you can join NCT06118723 on ClinicalTrials.gov

4. The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma

   Resection of glioblastoma in or near functional brain tissue is challenging because of the proximity of important structures to the tumor site. To pursue maximal resection in a safe manner, mapping methods have been developed to test for motor and language function during the operation. Previous ev…

   Stage

   Not phased

   Ages

   Up to 90

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   8 in total

   Run by

   Erasmus Medical Center

   See if you can join NCT06273176 on ClinicalTrials.gov

5. The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)

   There are no guidelines or prospective studies defining the optimal surgical treatment for gliomas of older patients (≥70 years) or those with limited functioning performance at presentation (KPS ≤70). Therefore, the decision between resection and biopsy is varied, amongst neurosurgeons internation…

   Stage

   Not phased

   Ages

   18 to 90

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   8 in total

   Run by

   Jasper Gerritsen

   See if you can join NCT06146725 on ClinicalTrials.gov

6. The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)

   There is no consensus on the optimal treatment of patients with high-grade glioma, especially when patients have limited functioning performance at presentation (KPS ≤70). Therefore, there are varied practice patterns around pursuing biopsy, resection, or palliation (best supportive care). This stu…

   Stage

   Not phased

   Ages

   18 to 90

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   8 in total

   Run by

   Jasper Gerritsen

   See if you can join NCT06146738 on ClinicalTrials.gov